• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

    2.090 +0.130 (+6.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fate Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Fate Therapeutics Appoints Laura Hamill to Board of Directors
    Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization 
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
    EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
    AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
    From USA News Group
    Via GlobeNewswire
    Friday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
    Issued on behalf of Avant Technologies Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.